---
title: HepaRegeniX
date: 2017-01-05T08:54:11Z
modified: 2026-08-13T11:32:58Z
permalink: "https://www.htgf.de/en/portfolio/htgffamily/heparegenix/"
type: portfolio
status: publish
excerpt: ""
wpid: 44157
language:
  - English
post_translations:
  - pll_586e09912ec73
branchen22:
  - Metabolic Diseases
sectors:
  - Pharmaceuticals
focus_areas:
  - Rejuventation
timestamp: 2026-08-13T11:32:58Z
tags:
  - English
  - pll_586e09912ec73
  - Metabolic Diseases
  - Pharmaceuticals
  - Rejuventation
---

## Beschreibungstext

Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). A first compound has recently started clinical development.
MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers. This new and unique therapeutic concept for the treatment of liver diseases was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.

## Adresse

HepaRegeniX GmbH
Eisenbahnstraße 63
D-72072 Tübingen

## Kontakt

Array

Array

Array